Multivalent vaccine composition with mixed carrier

Details Multivalent vaccine composition with mixed carrier Multivalent vaccine composition with mixed carrier

2011-01-04

2011-01-04

Duffy, Patricia A (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C424S244100

Reexamination Certificate

active

07862823

ABSTRACT:
The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosides are in the form of conjugates, coupled with a carrier protein. The composition contains at least two types of conjugates, each being at least characterised by a different protein carrier.

REFERENCES:
patent: 4372883 (1983-02-01), Matuhashi et al.
patent: 5623057 (1997-04-01), Marburg et al.
patent: 0 497 525 (1992-08-01), None
patent: 88/00056 (1988-01-01), None
patent: WO 88 00056 (1988-01-01), None
patent: 03/051392 (2003-06-01), None
Ahman et al (Pediatr. Infect. Dis. J. 15:134-9, 1996).
Anderson et al (J. Pediatr. 128:649-53, 1996).
Lee et al (Vaccine, 13(16):1533-1538, 1995).
C. Chu et al.: “Further Studies on the Immunogenicity ofHaemophilus influenzaeType B and Pneumococcal Type 6A Polysaccharide-Protein Conjugates”,Infection and Immunity, vol. 41, No. 1, Apr. 1983, pp. 245-256.
D.P. Greenberg et al.: “Factors Influencing the Immunogenicity of a Pneumococcal Conjugate Vaccine in Infants”,Pediatric Research, vol. 41, May 2-6, 1997, p. 121A.
G.R. Siber: “Pneumococcal Disease: Prospects for a New Generation of Vaccines”,Science, vol. 265, Sep. 2, 1994, pp. 1385-1387.
C.C.A.M. Peeters et al.: “Effect of Carrier Priming on Immunogenicity of Saccharide-Protein Conjugate Vaccines”,Infection and Immunity, vol. 50, No. 10, Oct. 1991, pp. 3504-3510.
R. Dagan et al.: “Reduced Response to Multiple Vaccines Sharing Common Protein Epitopes That Are Administered Simultaneously to Infants”,Infection and Immunity, vol. 66, No. 5, May 1998, pp. 2093-2098.
Wuorimaa, T. et al., “Tolerability and Immunogenicity of an 11-Valent Pneumococcal Conjugate Vaccine in Adults.”Vaccine. 19, pp. 1863-1869 (2001).
Wuorimaa, T. et al. “Tolerability and Immunogenicity of an Eleven-Valent Pneumococcal Conjugate Vaccine in Healty Toddlers.”Pediatr. Infect. Dis. J.20(3), pp. 272-277 (Mar. 2001).
Åhman, H. et al. “Dose Dependency of Antibody Response in Infants and Children to Pneumococcal polysaccharides Conjugated to Tetanus Toxoid.”Vaccine. 17, pp. 2726-2762;(1999).
Fattom, A. et at “Epitopic Overload at the Site of Injection May Result in Suppression of the Immune Response to Combined Capsular Polysaccharide Conjugate Vaccines.”Vaccine. 17, pp. 126-133 (1999).
Dagan, R. et al. “Reduced Response to Multiple Vaccines Sharing Common Protein Epitopes That Are Admilstered Simultaneously to Infants.”Infection and Immunity. 66(5), pp. 2093-2098 (May 1998).
Eick et al., “Safety and Immunogenicity of Two Octavalent Pneumococcal Conjugate Vaccines in American Indian Infants”, Vaccine 22, 2004, 1260-1264, Elsevier.
Nurkka et al., “Serum and Salivary Anti-Capsular Antibodies in Infants and Children Vaccinated With Octavalent Pheumococcal Conjugate Vaccines, PncD and PncT”, Vaccine 20, 2002, 194-201, Elsevier.
Marie-Paule Schitze et al.: “Carrier-Induced Epitopic Supperssion, A Major Issue for Future Synthetic Vaccines,” The Journal of Immunology, vol. 135, No. 4, Oct. 1985, pp. 2319-2322.
Marie-Paule Schutze et al.: “Carrier-Induced Epitopic Suppression is Initiated Through Clonal Dominance,” The Journal of Immunology, vol. 142, No. 8, Apr. 15, 1989, pp. 2635-2640.
Carla C. A. M. Peeters, et al.: “Effect of Carrier Priming on Immunogenicity of Saccharide-Protein Conjugate Vaccines,” Infection and Immunity, Oct. 1991, vol. 59, No. 10, pp. 3504-3510.
Ortqvist et al., “Pneumococcal Capsular Polysaccharide Vaccine (PCPV) for Prevention of Pneumonia in Middle-Aged and Elderly Persons: A Prospective, Randomized, Placebo-Controlled Multicenter-Trial”, Abstracts of the 36th ICAAC, 1 page, Tuesday Session 61, Nabi-Rockville, USA.
Lindberg AA, 1999, Vaccine, 17:S28-S36.
Ahman et al., 1996, 36th Intersc Conf Animicrob Agents and Chemotherapy, New Orleans, Abstr. G109, p. 162.
Assess the Immunogenicity of GSK Biological's 10-valent Pneumococcal conjugate, retrieved from the Internet on Sep. 20, 2007, http://www.clinicaltrials.gov/ct/show/NCT00307541.
Wuorimaa et al., Scand. J. Immunol. 56, 111-129, 2002.
Steinhoff, M.C. et al. (1994) A randomized comparison of three bivalentStreptococcus pneumoniaeglycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr. Infect. Dis. J. vol. 13 (5), pp. 368-372.
Chiu, S.S. et al. (1995) Safety and immunogenicity of a pentavalent pneumococcal conjugate vaccine (PPCV) in healthy toddlers. Presented at the 35th Intersc. Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G71, p. 171.
Daum, R.S. et al. (1995) Immunogenicity ofS Pneumoniaeoligo- and polysaccharide- CRM197 conjugate vaccines in healthy US infants. Presented at the 35th Intersc Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G 65, p. 170.
O'Brien, K.L. et al. (1996) Immunologic priming of young children by pneumococcal glycoprotein conjugate but not polysaccharide, vaccines Peditar. Infect. Dis. J. vol. 15 (5) pp. 425-430.
Rennels, M.B. et al. (1996) Abstract from Immunogenicity and Safety of 7-Valent Pneumococcal-CRM-197 Conjugate Vaccine. Pediatric Research, vol. 39 (4) part 2, p. 183A. Asbtr 1082.
Shelly, M.A. et al. (1997) Comparison of pneumococcal polysaccharide and CRM197 conjugated pneumococcal oligosaccharide vaccines in young and elderly adults Infection & Immunity vol. 65(1) pp. 242-247.
Kennedy, D. et al. (1994) Immunologic response of 12-18 months old children to licensed pneumococcal polysaccharide vaccine (PS) primed withStreptococcus pneumoinae19F conjugate vaccine (CV). Presented at the 34th Intersc Conf. Antimicrob. Agents and Chemotherapy Orlando Abstract G88, p. 236.
Nieminen, T. et al. (1994) Mucosal and serum immune response to tetravalent pneumococcal (SPn) conjugate vaccines (SpnD and SpnT) in adults. Presented at the 34th Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstract G89, p. 236.
Portier, H. et al. (1994) Serum antibody response to a tetravalent pneumococcal tetanus toxoid conjugate vaccine in adult volunteers. Presented at the 34th Intersc. Conf. Antimicorb. Agents and Chemotherapy Abstract G91, p. 236.
Keyserling, H. et al. (1994) Immunogenicity of type 14 conjugate vaccine in infants. Presented at the annual meeting of the American Pediatric Society/Society for Pediatric Research Seattle, WA. Abstract 1087, p. 184A.
Kennedy, D. et al. (1994) Immunologic response to licensed pneumococcal polysaccharide vaccine (PS) in infants primed with heptavalentStreptococcus pneumoniaeconjugated vaccine. Presented at the 34th Intersc. Conf. Antimicrob. Agents in Chemotherapy, Orlando Abstract G90, p. 236.
Kayhty, H. et al. (1995) Pneumococcal polysaccharide-menigococcal outer membrane protein complex conjugate vaccine is immunogneic in infants and children. J. Infect. Dis vol. 172, pp. 1273-1278.
Dagan, Ron et al. (1996) Reduction of Nasopharyngeal Carriage of Pneumococci during the Second Year of Life by a Heptavalent Conjugate Pneumococcal Vaccine. The Journal of Infectious Diseases vol. 174, pp. 1271-1278.
Sood, Ramesh K., et al., “Capsular Polysaccharide-Protein Conjugate Vaccines,” Research Focus Reviews, DDT, Sep. 1996, pp. 381-387, vol. 1, No. 9, Elsevier Science Ltd.
Sarnaik, Sharada MD, et al., “Studies onPneumococcusVaccine Alone or Mixed With DTP and onPneumococcusType 6B andHaemophilis influenzaeType b Capsular Polysaccharide-Tetanus Toxoid Conjugates in Two Five-Year-Old Children With Sickle Cell Anemia,” Pediatric Infect. Dis. J., vol. 9, pp. 181-6 (1990).
Andrew, P.W., et al., “Pneumococcal Vaccines,” Freer et al. (Eds.), Bacterial Protein Toxins, Zbl. Bakt. Suppl. 24, 1994, pp. 453-466, Gustave Fischer, Stuttgart, Jena, New York.
Dagan, Ron, et al., “Reduction o

Affiliated with

Also associated with

Rating

Multivalent vaccine composition with mixed carrier does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multivalent vaccine composition with mixed carrier, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent vaccine composition with mixed carrier will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2739430